The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Making the case for potential benefits of microdosing LSD and ‘magic’ mushrooms

| | March 13, 2019

[A]necdotal endorsements of [psychedelic] microdosing claim that the routine can lead to a whole variety of benefits, including heightened emotional sensitivity, athletic performance, and creativity; and relief from symptoms of anxiety, depression, OCD, PTSD, and chronic pain—all without resulting in any sort of trip.

In a lab setting, meanwhile, these effects have hardly been studied.

Now a new study published  in the journal ACS Chemical Neuroscience provides the first biological evidence that psychedelic microdosing could have unique therapeutic effects that differ from the effects of a full dose.

Olson’s team calculated a dosage of DMT—which is chemically like a stripped-down version of LSD or psilocybin “magic” mushrooms—that was too small to produce any hallucinogenic effects. They gave it to the rats every three days. On off days, the animals completed tests, including two experimental proxies for human anxiety and depression.

Related article:  How long can bacteria live? 500-year experiment could provide answers

Seven weeks later, the researchers found that even though the rats weren’t given enough DMT to hallucinate, their depression and anxiety scores still improved significantly.

Olson says the study demonstrates that the therapeutic effects of psychedelics—in rats, at least—can indeed be harnessed independently of the hallucinogenic effects.

Read full, original post: A New Chapter in the Science of Psychedelic Microdosing

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend